CompoAtlas

HORBÄACH - L-GLYCINE 1500MG

Food supplement declared in France, decision dated 10 November 2025

HORBÄACH - L-GLYCINE 1500MG, from PIPING ROCK UK LIMITED, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Glycine. None of the rules we check flags an issue with its declared composition.

Brand
not provided
Food business operator placing the product on the market
PIPING ROCK UK LIMITED
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Tablet
Daily dose
3 TABLETS
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Pregnant women, Taking medication

Declaration 344717, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Other active ingredients

NamePer day
Glycinenot declared

Additives

E470b, E341, E460

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Consult a doctor before use if you are pregnant, breastfeeding, taking medication, or have a medical condition.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “HORBÄACH - L-GLYCINE 1500MG: composition and regulation”, https://compoatlas.com/en/supplements/products/344717-horbaach-l-glycine-1500mg, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line